30-second summary
Theranos raised $945M on the promise of hundreds of tests from a single finger-prick, dissolved when journalists and regulators confirmed the tests were being run on competitors' equipment behind the curtain. Criminal fraud conviction of the founder in 2022. The revival question for this entry is not "how would we rebuild it" — it is "what does this failure warn against for anyone pitching a healthcare-hardware-plus-software bundle in 2026."
The Pitch
One drop of blood, hundreds of tests, a tabletop Edison device in your local Walgreens. Insurance-grade results at a tenth of the cost, on demand. The pitch was a complete consumer and provider story wrapped together, which is part of why it raised so easily.
Five Causes of Death
Market
The underlying demand — cheaper, faster, finger-prick-scale blood tests — is real and persistent. But the unit of test is not flexible in the way Theranos described. Many assays genuinely require sufficient sample volume, and no software or miniaturization collapses that requirement. The pitch was selling a market shape that didn't match the physics.
Product
The Edison device did not work. Investigative reporting confirmed that in the moments Theranos ran tests for real customers, it often ran them on modified Siemens Advia analyzers — off-the-shelf incumbent machines — not on its own hardware. The company's technical claim was never validated in peer-reviewed literature before billion-dollar rounds closed.
Team
The founding team lacked deep biotech operator experience and the board lacked scientific oversight — Kissinger, Shultz, and Mattis are political heavyweights, not assay chemists. This pattern is the warning: a healthcare company with a board that can't read its own validation data is a fraud waiting to be discovered.